Stable Retinal Gene Expression in Nonhuman Primates via Subretinal Injection of SIVagm-Based Lentiviral Vectors
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Abstract Gene therapy may hold promise as a therapeutic approach for the treatment of intractable ocular diseases, including retinitis pigmentosa (RP). Gene transfer vectors that are able to show long-lasting transgene expression in vivo are highly desirable to treat RP; however, there is a dearth of information regarding long-term transgene expression in the eyes of large animals. We previously reported that the simian immunodeficiency virus from African green monkeys (SIVagm)-based lentiviral vector showed efficient, stable, and safe retinal gene transfer, resulting in significant prevention of retinal degeneration by gene transfer of a neurotrophic factor, human pigment epithelium-derived factor (hPEDF), in rodents. Before applying this strategy in a clinical setting, we here assessed the long-lasting transgene expression of our third-generation SIVagm-based lentiviral vectors in the retinal tissue of nonhuman primates. Approximately 20-50 mul of SIV-EGFP (enhanced green fluorescent protein) or SIV-hPEDF was injected into the subretinal space via a glass capillary tube. To detect EGFP expression in the retina, we used a fluorescence fundus camera at various time points after gene transfer. Human PEDF expression was assessed by immunohistochemical analysis, Western blot assay, and enzyme-linked immunosorbent assay. The retinas demonstrated frequent EGFP expression that was preserved for at least 4 years without significant decline. The expression of hPEDF was stable, and occurred mainly in the retinal pigment epithelium. The secreted protein was detected in vitreous and aqueous humor. We thus propose that SIVagm-mediated stable gene transfer might be significantly useful for ocular gene transfer in a clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“The efficacy of gene therapy using an adeno-associated virus (AAV) vector for Leber’s congenital amaurosis (LCA) was reported by two groups (Bainbridge et al., 2008; Maguire et al., 2008).”
Chévez-Barrios, P., Chintagumpala, M., Mieler, W., Paysse, E., Boniuk, M., Kozinetz, C., Hurwitz, M. Y., & Hurwitz, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.1883 · Cited by 143 · cited 1×
“A phase 1 clinical trial evaluating the safety of adenoviral vector-mediated gene therapy in patients with wet age-related macular degeneration (AMD) or retinoblastoma has been completed, and no dose-limiting toxicities or drug-related serious adverse events have been observed to date (Rasmussen et al., 2001; Chévez-B…”
Lotery, A. J., Yang, G. S., Mullins, R. F., Russell, S. R., Schmidt, M., Stone, E. M., Lindbloom, J. D., Chiorini, J. A., Kotin, R. M., & Davidson, B. L. (2003) · Human Gene Therapy · doi:10.1089/104303403322542301 · Cited by 107 · cited 1×
“, 2002), despite the many reports of efficient transfer by recombinant adenoassociated virus (rAAV) vectors (Bennett et al., 1999; Lotery et al., 2003; Le Meur et al., 2005).”
Duisit, G., Conrath, H., Saleun, S., Folliot, S., Provost, N., Cosset, F.-L., Sandrin, V., Moullier, P., & Rolling, F. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0690 · Cited by 79
Ikeda, Y., Goto, Y., Yonemitsu, Y., Miyazaki, M., Sakamoto, T., Ishibashi, T., Tabata, T., Ueda, Y., Hasegawa, M., Tobimatsu, S., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301973 · Cited by 30
Self-citation
Cited by
A comprehensive review of retinal gene therapy
Boye, S. E., Boye, S. L., Lewin, A. S., & Hauswirth, W. W. (2013) · Molecular Therapy · doi:10.1038/mt.2012.280 · Cited by 262
Subretinal injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases
Peng, Y., Tang, L., & Zhou, Y. (2017) · Ophthalmic Research · doi:10.1159/000479157 · Cited by 175
Binley, K., Widdowson, P., Loader, J., Kelleher, M., Iqball, S., Ferrige, G., de Belin, J., Carlucci, M., Angell-Manning, D., Hurst, F., et al. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-11871 · Cited by 115
Lentiviral vectors for ocular gene therapy
Arsenijevic, Y., Berger, A., Udry, F., & Kostic, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081605 · Cited by 47
“The toxicological profile was evaluated as promising with minimal effect on retinal function (measured by electroretinogram (ERG)) and inflammation while presenting a long-term expression [75,81].”
Background
Metadata
- Authors
- Ikeda, Y., Yonemitsu, Y., Miyazaki, M., Kohno, R.-I., Murakami, Y., Murata, T., Tabata, T., Ueda, Y., Ono, F., Suzuki, T., Ageyama, N., Terao, K., Hasegawa, M., Sueishi, K., & Ishibashi, T.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2009-06
- Volume
- 20
- Issue
- 6
- Pages
- 573-579
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W1986668568
- Cited by
- 21
- References
- 5
- FWCI
- 0.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.